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Quantiﬁcation of the neurochemical proﬁle
using simulated macromolecule resonances
at 3 T
Benoît Schallera, Lijing Xinb*, Cristina Cudalbua and Rolf Gruettera,b,c
The broad resonances underlying the entire 1H NMR spectrum of the brain, ascribed to macromolecules, can
inﬂuence metabolite quantiﬁcation. At the intermediate ﬁeld strength of 3 T, distinct approaches for the determina-
tion of the macromolecule signal, previously used at either 1.5 or 7 T and higher, may become equivalent. The aim of
this study was to evaluate, at 3 T for healthy subjects using LCModel, the impact on the metabolite quantiﬁcation of
two different macromolecule approaches: (i) experimentally measured macromolecules; and (ii) mathematically
estimated macromolecules. Although small, but signiﬁcant, differences in metabolite quantiﬁcation (up to 23% for
glutamate) were noted for some metabolites, 10 metabolites were quantiﬁed reproducibly with both approaches
with a Cramer–Rao lower bound below 20%, and the neurochemical proﬁles were therefore similar. We conclude
that the mathematical approximation can provide sufﬁciently accurate and reproducible estimation of the
macromolecule contribution to the 1H spectrum at 3 T. Copyright © 2013 John Wiley & Sons, Ltd.
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INTRODUCTION
Localized 1H MRS allows direct and noninvasive insights into brain
metabolism. The spectral resolution and signal-to-noise ratio of 1H
MRS improve with the mainmagnetic ﬁeld B0 (1), enabling gains in
accuracy and precision of the quantiﬁcation of many brain meta-
bolites constituting the neurochemical proﬁle at short TE (2–8).
However, the accuracy of the metabolite quantiﬁcation at short
TE is hampered by the presence of broad resonances, which
underlie the whole 1H spectrum, ascribed to macromolecules (e.g.
cytosolic proteins) and characterized by short T1 and T2 (9–11)
and an apparent diffusion coefﬁcient 10–20 times lower than that
of metabolites (12). In addition, themacromolecule contribution to
the 1H spectrum may change with pathology (13–16). Thus, an
accurate and appropriate estimation of the macromolecule
contribution to the 1H spectrum is desired to avoid quantiﬁcation
errors of the neurochemical proﬁle (13,17–19).
Several strategies to assess themacromolecule signal have been
explored, which are dependent on the ﬁeld strength (17–26). At
low ﬁeld strength (below 3 T), macromolecules have generally
been estimated mathematically using spline or wavelets (22), or
during a pre-processing step using the early time points of the
time domain signal, which are considered to represent mainly
the macromolecule signal because of the relatively short T2* (26).
However, at high ﬁeld strength (above 3 T), the linewidth of the
macromolecule resonances approaches that of the J-coupled
metabolite resonances, compromising a mathematical estimation
of the macromolecule signal, which cannot be differentiated from
the metabolite resonances (11,27,28). Therefore, the in vivo
acquisition of the macromolecule contribution is required for an
accurate quantiﬁcation of the neurochemical proﬁle (17,18,21,29).
However, 3 T is an intermediate ﬁeld strength for which the mac-
romolecule signal might be reliably estimated eithermathematically
or experimentally, and the appropriate technique is still under
debate (19). A recent study (25) has investigated two approaches
to measure the macromolecule signal contribution to the metabo-
lite quantiﬁcation at 3 T using QUEST (QUantitation based on
quantum ESTimation) (23), and has reported that the metabolite-
nulling technique results in an increased accuracy of the quantiﬁ-
cation and a wider range of quantiﬁed metabolites relative to the
initial signal truncation technique in the time domain. However,
the measurement of the macromolecules with the metabolite-
nulling technique is time consuming.
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As an alternative method, LCModel is widely used and allows
accurate metabolite quantiﬁcation in the frequency domain
(20,30–32). The macromolecule signal is thus approximated by a
spline function built into LCModel and, optionally, with simulated
macromolecule resonances. The experimental measurement of
the macromolecules has not been compared previously with the
mathematical estimation investigated with LCModel at 3 T.
Therefore, the aim of this study was to evaluate the differences
between the experimentally measured macromolecules and the
mathematically estimatedmacromolecules, and to determine their
relative impact on the metabolite quantiﬁcation at 3 T.
MATERIALS AND METHODS
Subjects and MR protocol
Eleven healthy subjects (three women and eight men; age,
20–30 years) gave informed consent according to the procedure
approved by the local ethics committee. The experiments were per-
formed on a 90-cm-bore clinical 3-T scanner (Magnetom Trio, a Tim
System, Syngo MR VB17 Siemens, Erlangen, Germany) equipped
with a whole-body gradient coil [40 mT/m, 200 mT/(mms)], and
data were acquired using a transverse electromagnetic volume coil
(MR Instruments, Inc., Minneapolis, MN, USA). The volume of interest
(20 20 25mm3) was located in the frontal lobe predominantly
composed of gray matter and surrounded by a shim volume
(30 30 35mm3) (inset Fig. 1). First- and second-order shims
were adjusted using automated FAST (EST) MAP (fast automatic
shimming technique by mapping along the projections) (33,34),
which provided a homogeneous B0 ﬁeld over the volume of interest.
Macromolecule spectra were acquired with the spin echo full in-
tensity acquired localized (SPECIAL) sequence [TR/TE= 4000/6ms;
vector size, 2048 pts; number of transients (NT), 32 4] (4,35)
preceded by an inversion pulse (duration, 5.12ms; bandwidth,
4 kHz; peak B1 amplitude gB1max/2 of 1.4 kHz) to minimize
the metabolite contributions. A VAPOR (variable power RF
pulses with optimized relaxation delays) water suppression
interleaved with blocks of outer volume suppression (36) was
placed prior to the sequence to minimize the water signal and
lipid signal from extracerebral fat tissue. The location of the
voxel and the placement of the outer volume suppression
bands were carefully positioned to minimize lipid contamina-
tion. A preliminary experiment was conducted with a healthy
subject to measure the macromolecule signal with a set of
different inversion times (TI = 650, 700, 750 and 800ms) to
determine the optimum TI for the acquisition of the macromole-
cule spectrum with minimum metabolite residuals. Then, the
macromolecule signal was acquired with a ﬁxed TI of 750ms for
four subjects (four men). In vivo 1H spectra were acquired for seven
subjects (three women and four men) using the SPECIAL localiza-
tion sequence (TR/TE= 4000/6ms; vector size, 2048 pts; NT=148)
without an inversion pulse.
Data processing
After Fourier transformation, individual spectra were manually
phase corrected. Then, a frequency correction was applied to
all spectra for the small B0 drift occurring during the acquisition
by aligning the macromolecule peak at 0.89 ppm using Matlab,
as described in Tkac and Gruetter (36). Finally, spectra were
averaged over four subjects in a summed macromolecule
spectrum of 512 scans (128 scans per subject). As a result of
the heterogeneity of the T1 value of the metabolites (27), the
averaged macromolecule spectrum contained small metabolite
residuals.
First, the water residual was ﬁltered from the macromolecule
spectrum and metabolite residuals were modeled with jMRUI us-
ing AMARES (advanced method for accurate, robust and efﬁcient
spectra) (37). As described by Craveiro et al. (38), a set of singlet
lorentzian functions was used with constraints on linewidth, fre-
quency, phase and amplitude to compensate for the metabolite
residuals that were to be removed. The setting of the parameters
included prior knowledge on the phase (0 for positive residuals
and 180 for negative residuals) and the central frequencies of
the metabolite residuals (creatine (Cr) at 3.01 and 3.9 ppm and
N-acetylaspartate (NAA) at 2.01ppm). The amplitude and linewidth
of the singlet lorentzian functions were adjusted in order to ﬁt the
metabolite residuals of the macromolecule spectrum. Finally, the
modeled ﬁts of the metabolite residuals were subtracted from
the macromolecule spectrum to provide a metabolite-free macro-
molecule spectrum. To reduce the noise of the corrected macro-
molecule spectrum, a line broadening of 2Hz was applied prior
the creation of the basis sets.
Plots of the macromolecule spectrum for both approaches
and the spline baseline after LCModel analysis are represented
in the ﬁgures as the mean (thick line) and the standard deviation
(SD) (n=7, shaded area).
Figure 1. (A) 1H spectrum acquired with SPECIAL [ TR/ TE = 4000/6 ms;
number of transients (NT), 148] allowing the quantiﬁcation of 14 metabo-
lites with Cramér–Rao lower bound (CRLB) < 30%. Asp, aspartate; Cr,
creatine; GABA, g-aminobutyric acid; Glc, glucose; Gln, glutamine; Glu,
glutamate; GSH, glutathione; Ins, myo-inositol; Lac, lactate; NAA, N-
acetylaspartate; PCr, phosphocreatine; Scyllo, scyllo-inositol; Tau, taurine.
(B) The macromolecule spectrum measured with the inversion recovery
technique (NT = 512, TI = 750 ms) before correction averaged over four
subjects. Metabolite residuals were observed for Cr (3.01 and 3.9 ppm)
and NAA (2.01 ppm) and were ﬁtted with jMRUI (AMARES) (C). (C) was
subtracted from (B) to provide a metabolite-free macromolecule spec-
trum (D). Inset: location of the voxel (20  20  25 mm3) surrounded
by the shim volume (30  30  35 mm3) in the frontal cortex. Spectra
were line broadened by 2 Hz.
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Metabolite quantiﬁcation
All spectra were ﬁtted and quantiﬁed with LCModel (20) using
two basis sets. Both included 20 simulated spectra of metabo-
lites using published values for chemical shift and J coupling
(39,40), but with different macromolecule approaches: (i) the
metabolite-nulled macromolecule spectrum measured with the
inversion recovery technique was integrated as prior knowledge
in the basis set; and (ii) the mathematically estimated macromo-
lecules using LCModel-simulated macromolecule resonances.
Both approaches were completed with built-in spline functions.
In the second approach, eight simulated macromolecule reso-
nances provided by LCModel were included in the analysis at
the following positions: 0.91, 1.21, 1.43, 1.67, 1.95, 2.08, 2.25
and 3 ppm. Residual water was removed with jMRUI (AMARES)
from all the 1H spectra. All 1H spectra were ﬁtted and metabolite
concentrations were quantiﬁed with LCModel using the two
aforementioned basis sets. The LCModel analysis was carried
out from 0.2 to 4.2 ppm and a Cr concentration of 8.5 mmol/g
was assumed for the scaling of the metabolite concentrations.
The Cramér–Rao lower bound (CRLB) measures the reliability
of the ﬁtted parameters by assuming that the model function
is correct, and was thus used as a marker of the precision of
the quantiﬁcation (20,41,42). Only ﬁtted metabolite concentra-
tion parameters with a mean CRLB below 30% were retained
for further analysis. If a metabolite was quantiﬁed with CRLB
above 30% for at least two subjects, this metabolite was
excluded from further analysis. However, somemetabolites with
CRLB above 30% are reported in Table 1 for comparison. To
evaluate the inﬂuence of each approach on the quantiﬁcation,
a statistical analysis was performed using a two-way analysis
of variance (ANOVA). Metabolite quantiﬁcation differences
with p values below 0.05 were considered to be statistically
signiﬁcant. Metabolite concentration and CRLB are expressed as
the mean  SD.
RESULTS
Experimentally measured macromolecule signal
Metabolite residuals were observed in all macromolecule spec-
tra, but were not identical because of the different T1 values of
the metabolite resonances (27). The identiﬁcation of the metab-
olite residuals was based on the time courses of their respective
intensities for different TIs and was in agreement with the T1
values reported at 3 T (27). Consequently, a macromolecule
spectrum with nulled metabolite resonances could not be
acquired. Nevertheless, TI = 750ms was set for the acquisition of
the macromolecule spectrum because of the presence of the
smallest metabolite residuals, and retained for the following mac-
romolecule acquisitions. These incomplete nulled metabolites
were observed in the acquired macromolecule spectrum (Fig. 1B)
and consisted of two inverted peaks assigned to NAA (2.01ppm)
and Cr (3.01ppm) and a positive peak of Cr (3.9 ppm).
Next, a macromolecule signal was measured over four sub-
jects and averaged (Fig. 1B). The observed SD varied with the
spectral region and was, on average, 3 1 from 0.5 to 1.7 ppm,
3 2 from 1.7 to 3.2 ppm and 7 4 from 3.2 to 4.2 ppm (n= 4).
These values are expressed in arbitrary units (a.u.) and are
reported here only as a point of comparison (with the same
scale, the macromolecule peak at 0.89 ppm was 100 a.u.).
To eliminate the metabolite residuals of the measured macro-
molecule spectrum (Fig. 1B), a correction was applied after
averaging using jMRUI (AMARES), as described previously (see
Data processing and Fig. 1C). It thus provided a metabolite-nulled
Table 1. Cramér–Rao lower bounds (CRLBs) (mean  standard deviation) obtained from LCModel analysis of 1H spectra (n = 7)
using the experimentally measured macromolecules or mathematically estimated macromolecules. Fourteen metabolites were
quantiﬁed with a mean CRLB below 30% for both approaches
CRLB (%)
Metabolite Experimentally measured macromolecules Mathematically estimated macromolecules
Aspartate 13  3 14  4
Creatine 5  1 5  1
Phosphocreatine 7  1 7  1
g-Aminobutyric acida 35  11 17  3
Glutamine 16  4 28  10
Glutamate 4  1 6  1
Glutathione 12  4 10  3
myo-Inositol 5  1 5  1
Lactate 19  3 29  6
N-Acetylaspartate 2  0 2  0
scyllo-Inositol 17  5 18  6
Taurine 26  10 29  11
Glucose 26  15 20  9
Phosphorylethanolamine 8  1 9  1
Total NAA 2  0 2  0
Total choline 3  1 3  1
Glu + Gln 4  1 6  1
CRLB in italic signiﬁes that one or two subjects had CRLB above 30%.
aGABA had four subjects with CRLB above 30% when using the experimentally measured macromolecules.
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macromolecule spectrum (Fig. 1D), which formed the basis of the
macromolecule model used for the subsequent LCModel analysis.
Macromolecule signal and LCModel analysis
In vivo 1H NMR spectra were acquired for seven subjects (NT=148)
andwere judged to be of high quality based on the high sensitivity
of the 1H spectra and the absence of extracerebral lipid signals
(Fig. 1A). Adjustments of ﬁrst- and second-order shims resulted in
an average water linewidth of 6.3 0.1Hz (mean  SD).
To compare the two different macromolecule estimations,
in vivo 1H spectra (n= 7) were subjected to LCModel analysis
using two approaches: (i) the measured and further processed
macromolecule spectrum (averaged over four subjects, see above)
(Fig. 2A); and (ii) the mathematical estimation of the macromole-
cule signal (Fig. 2B). The ﬁtted spectra demonstrated a goodmatch
with the acquired 1H spectra for both methods, judging from the
ﬂat, noisy ﬁtting residual. It should be noted that, from 0.5 to
4.2 ppm, the SD of the mean macromolecule signal ﬁt was below
6% (Fig. 2A, third spectrum from the top).
To further investigate the similarities between the two
approaches, the measured macromolecule signal (experimentally
measured macromolecules plus spline baseline) was subtracted
from the mathematically estimated macromolecule signal
(simulated macromolecules plus spline baseline) (Fig. 3A). The
two signals showed good agreement (Fig. 3A, top) and the differ-
ence signal (Fig. 3A, bottom) overall exhibited a ﬂat residual,
except for some minor changes: the macromolecule signal of the
ﬁrst approach was slightly higher at 1.9 and 3.2 ppm, and lower
at 2.1, 2.4 and 3.8 ppm, than the second approach.
To determine the inﬂuence of the two approaches on the
quantiﬁcation, the concentration of the metabolites (mean SD)
and their CRLB (mean SD) were calculated from both LCModel
analyses for seven subjects and compared (Fig. 3B and Table 1).
The analysis of the 1H spectra allowed the quantiﬁcation of 14
metabolites for both methods, 10 of which had CRLB below 20%
[aspartate (Asp), total choline (tCho), Cr, phosphocreatine (PCr),
glutamate (Glu), glutathione (GSH), myo-inositol (Ins), NAA, scyllo-
inositol (Scyllo) and phosphorylethanolamine (PE)] and four of
which had CRLB below 30% [glucose (Glc), glutamine (Gln), lactate
(Lac) and taurine (Tau)]. g-Aminobutyric acid (GABA) was quanti-
ﬁed with CRLB below 30% only when using the spline approxima-
tion. Overall, the metabolite quantiﬁcation of the two approaches
was similar and the metabolite concentration differences were
below 15% for most metabolites. However, Glu and GSH showed
signiﬁcant concentration differences exceeding the aforemen-
tioned 15% level, i.e. 23% (p< 0.001) and –33% (p< 0.05), respec-
tively. Low concentration metabolites, such as Gln, GABA and Glc,
showed relatively high concentration differences (25–100%) and
are reported in Fig. 3B. However, because of their high CRLB differ-
ences (absolute change of 8–20%), they were excluded from the
statistical comparison (i.e. metabolite concentrations are shown,
but p values were not reported). It should also be noted that,
between the ﬁrst and second approaches, the GABA concentration
doubled, but the CRLB halved in percentage.
DISCUSSION
This study reports that the neurochemical proﬁle of 10 metabo-
lites can be reliably quantiﬁed with CRLB below 20% at 3 T for
healthy subjects when using two different approaches for
macromolecule estimation, namely: (i) the experimentally mea-
sured in vivo macromolecule spectrum; and (ii) the mathematical
estimation of the macromolecule signal. Metabolite concentration
differences between the two approaches were within SD for all the
metabolites and below 15%, except for Glu (23%, p< 0.001) and
Figure 2. 1H NMR spectra (top; NT=148) of seven subjects were quantiﬁed with LCModel using the experimentally measured macromolecules
(A) or mathematically estimated macromolecules (B). From top to bottom: the 1H spectrum (ﬁtted and real spectrum), ﬁtting residual, corrected
macromolecule signal (left) and simulated macromolecules (right), the spline baseline and the sum of the last two. The curves are represented as
the mean (black)  standard deviation (shaded area).
B. SCHALLER ET AL.
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GSH (–33%, p< 0.05). The small disparities of the obtained metab-
olite concentrations and CRLBs between the two methods were
consistent with the differences between the macromolecule
estimation of the two approaches.
The macromolecule spectra were experimentally measured by
an inversion recovery experiment with an inversion time set to
750ms and averaged over four subjects (Fig. 1B). The residual
water signal of the averaged macromolecule spectrum was
ﬁltered with jMRUI (AMARES) and phase corrected. As a result
of the high signal-to-noise ratio, metabolite residuals were iden-
tiﬁed and removed (Fig. 1C) using jMRUI (AMARES), providing a
metabolite-free macromolecule spectrum (Fig. 1D). The small
SD of the averaged macromolecules illustrated the overall stabil-
ity and reproducibility of the experiment, and enabled the use of
an averaged measured macromolecule signal (NT = 512 scans) to
quantify the 1H spectra of healthy subjects (n= 7 Fig. 2). How-
ever, the mean SD of the averaged macromolecule spectrum
was two-fold higher from 3.2 to 4.2 ppm relative to 0.5 to
1.7 ppm (data not shown). The ﬁltering of the residual water of
the macromolecule spectra helped to reduce the SD, but some
small variation remained, probably as a result of intersubject
variation. In general, the measured macromolecule baseline
was extremely stable between subjects, and such stability may
be harder to achieve in pathology. Thus, the acquired and pro-
cessed macromolecule spectrum was used in the LCModel basis
set for 1H spectra quantiﬁcation (n= 7).
In vivo 1H spectra were acquired for seven subjects and ﬁtted
with LCModel using the same metabolite basis set, but two
different macromolecule approaches: the measured macromol-
ecule spectrum or the simulated macromolecule resonances
and the built-in spline function. In the ﬁrst approach (Fig. 2A),
the macromolecule ﬁt showed small SD (within 6%), which
probably reﬂects the small variability of macromolecules
between subjects in the frontal lobe. Residual water ﬁltering
contributed to the aforementioned small SD and also to a ﬂat
spline baseline. Concerning the mathematical approach
(Fig. 2B), the simulated macromolecule resonances also exhib-
ited a small SD (within 7%), but ranged only from 0.91 to
3 ppm. Hence, the spline baseline accommodated the entire
macromolecule signal in the 3–4-ppm range and showed higher
ﬂuctuation in this range.
The concentrations of 13 metabolites were quantiﬁed with
a mean CRLB below 30%. The aforementioned differences
between the ﬁts of each approach (the measured macromole-
cules and the mathematically estimated macromolecules) led
to some relative quantiﬁcation differences (Fig. 3 and Table 1).
The mathematically estimated macromolecules were slightly
higher at 2.1, 2.4 and 3.8 ppm, which led to an underestimation
of the Glu and Gln concentrations when compared with those
obtained using the experimentally measured macromolecules.
However, GABA, GSH and NAA concentrations were overesti-
mated, probably as a result of the macromolecule differences
at 1.9 and 3.2 ppm. The concentration and CRLB differences were
within SD for all reliably quantiﬁed metabolites (CRLB below
30%), except for Glu (Fig. 3B). These changes were relatively small,
but were systematic, and thus statistically signiﬁcant, for Glu, NAA,
total NAA (tNAA) and Glu+Gln (p< 0.05). Gln and Glc are low
concentration metabolites and their concentration differences
were also signiﬁcant; however, these changes were comparable
with their respective CRLBs when expressed in concentration
units, and thus are probably below experimental error, when
including, for example, inter-individual differences. The CRLB of
the metabolites quantiﬁed with CRLB< 30% (Table 1) differed
slightly between the two approaches (within 2%), with the
exception of Gln (+12%), Lac (+10%) and Glc (–6%).
GABA is a low concentration metabolite and its concentration
difference between the two approaches was also signiﬁcant. The
current literature states a GABA concentration around 1mmol/g or
lower (43–45). In our study, when using the experimentally mea-
sured macromolecules, the GABA concentration was 1.0 0.3
mmol/g (CRLB=35 11%, n=7). However, when using the math-
ematically estimated macromolecules, the GABA concentration
was 2.0 0.3mmol/g (CRLB=17 3%, n=7). Our results suggest
that the inclusion of an experimentally measured macromolecule
spectrum at 3 T may provide a GABA concentration that is in good
agreement with literature values.
In general, an overestimation or underestimation of the
macromolecule signal may inﬂuence strongly the CRLB of the
metabolites with low concentration but, overall, the metabolite
concentrations were fairly similar between the two approaches
and were in agreement with previous studies (45–47). The
location of the voxel in the frontal lobe suggests a composition
of predominantly gray matter. Therefore, the Glu concentration
seems to be closer to literature values (45,47) when using the
measured macromolecule baseline for the LCModel analysis
relative to the mathematical approach.
In addition, the macromolecule signal was investigated (data
not shown) using only the built-in spline in the LCModel analysis
(i.e. simulated macromolecule resonances were not included).
The neurochemical proﬁle between the two mathematical
Figure 3. (A) Overlap of the ﬁts obtained after LCModel analysis of the
in vivo measured macromolecule spectrum after correction (broken line)
and the simulated macromolecules (full line) with their respective spline
baseline. Difference signal by subtraction of the two ﬁts was also
obtained (bottom). Variations between the ﬁts leading to metabolite
quantiﬁcation differences are highlighted in gray. (B) Metabolite quanti-
ﬁcation (mean  SD, n = 7) of the 1H spectrum using the mathematically
estimated macromolecules (white) and the in vivomeasured macromole-
cules (black). A two-way analysis of variance (ANOVA) measured the
signiﬁcance of the changes between the two approaches (*p < 0.05,
***p < 0.001). Metabolite concentrations were scaled to a creatine con-
centration of 8.5 mmol/g.
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approaches was similar, but quantiﬁcation differences were signif-
icant for Glu, Gln and GABA and a higher CLRB for Lac was
observed. The Glu, Gln and GABA concentrations obtained when
using only the built-in spline to estimate themacromolecule signal
were between those obtained with the two approaches studied.
A previous study at 3 T (25) investigated the approximation of
the macromolecule signal contribution by focusing on the mea-
sured metabolite-nulled macromolecule signal and the macromol-
ecule baseline modeled by Subtract-QUEST (jMRUI). Gottschalk
et al. (25) concluded that the measured macromolecules enabled
a more accurate quantiﬁcation and that the use of the baseline
computed by Subtract-QUEST would result in a loss of metabolic
information. However, in our study, the proﬁle of the macromole-
cule signal of the two approaches (experimentally measured and
mathematically estimated) showed strong similarities (Fig. 3A) with
similar quantiﬁcation. The aforementioned concentration differ-
ences were generally small (Fig. 3B) and CRLBs were equivalent,
but generally smaller, when using the measured macromolecules
(Table 1). It should also be noted that Asp, Scyllo and PE were
quantiﬁed with CRLB below 20% using both methods, in addition
to the seven quantiﬁed metabolites reported previously (25).
The ﬁeld dependence of the linewidth, imposing the measure-
ment of macromolecules at high ﬁeld for reliable quantiﬁcation
(18), does not prevail in our study conducted at 3 T, and no
distinction, when using the experimentally measured macromol-
ecule signal or the mathematically estimated macromolecules,
could be made based on the metabolite concentration and CRLB
provided by LCModel analysis.
Macromolecules may vary with pathology, and can be consid-
ered as disease markers (13–16). Practically, macromolecule reso-
nances can be altered differently depending on the studied
spectral region and the stage of the disease. In these cases, the
adaptability of the mathematical estimation probably allows a
closer approximation of the macromolecule baseline than does
the use of a general prepared macromolecule signal averaged
from healthy volunteers, as the macromolecule resonances can
be affected differentially by disease.
We conclude that the experimentally measured macromole-
cule signal and the mathematically estimated macromolecule
signal provide a similar neurochemical proﬁle. Given the small
concentration differences of the ensuing LCModel quantiﬁca-
tion, we suggest that, at 3 T, the mathematical approximation is
a sufﬁcient estimation of the macromolecule contribution to 1H
spectra at 3 T. As a caveat, small, but signiﬁcant, differences in
the quantiﬁcation may need to be taken into account when
comparing metabolite concentrations obtained with these two
different approaches, such as for Glu and for GABA, which were
more reliably quantiﬁed when using the measured macromole-
cule baseline.
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